NAM
RARE icon

Nexpoint Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Nexpoint Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,722
Closed -$202K – 262
2019
Q4 		$202K Hold
4,722
– – 0.02% 260
2019
Q3 		$202K Buy
+4,722
New +$257K 0.01% 304

Other funds holding RARE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nexpoint Asset Management's RARE Position: Q1 2020 in Review

Nexpoint Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2020, closing a stake of 4,722 shares — an estimated $202K sold.

Nexpoint Asset Management first reported a position in RARE in Q3 2019 and held it in 2 quarters. The position peaked at $202K in Q4 2019. 174 funds tracked by Wall St. Rank hold RARE as of Q1 2020.

  • Nexpoint Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q1 2020 after selling out during the quarter.
  • Nexpoint Asset Management sold 4,722 Ultragenyx Pharmaceutical shares in Q1 2020, an estimated $202K.
  • Nexpoint Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and held it in 2 quarters.
  • Nexpoint Asset Management's Ultragenyx Pharmaceutical position peaked at $202K in Q4 2019.
  • 174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2020.

Based on Nexpoint Asset Management's 13F filing for Q1 2020, filed 15 May 2020.